The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.
Kiwamu Okita
Employment or Leadership Position - Shimonoseki Kosei Hospital
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Hiromitsu Kumada
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Research Funding - Eisai
Kenji Ikeda
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Masatoshi Kudo
Honoraria - Eisai
Seiji Kawazoe
No relevant relationships to disclose
Yukio Osaki
Honoraria - Eisai
Masafumi Ikeda
No relevant relationships to disclose
Toshiyuki Tamai
Employment or Leadership Position - Eisai
Takuya Suzuki
Employment or Leadership Position - Eisai